Targetnaya terapiya raka pochki


Cite item

Full Text

Abstract

Хотя в 70–80% случаев рак почки диагностируются на стадии локализованного опухолевого процесса, более чем у 1/2 пациентов после оперативного лечения развиваются метастазы [4]. Прогноз течения заболевания при развитии метастатического процесса у больных почечно-клеточным раком крайне пессимистичный: при отсутствии специфического лечения период до прогрессирования составляет 2–4 мес, а средняя продолжительность жизни после выявления метастазов не более 10–13 мес.Несмотря на резистентность к цитостатической и гормональной терапии, опухоли почки обладают определенной чувствительностью к иммуногенным воздействиям. Известны феномен "спонтанной регрессии" метастазов рака почки, а также случаи длительной ремиссии при отсутствии специфического лечения, что косвенно свидетельствует об иммунозависимости опухолевых клеток [9, 10]. Иммунотерапия цитокиновыми препаратами (интерферон-α – ИФН-α и интерлейкин-2 – ИЛ-2) является в настоящее время основным методом лечения метастатического рака почки.Новым перспективным направлением в лечении больных метастатическим раком почки является применение таргетных препаратов, которое позволяет повысить эффективность терапии у этой категории пациентов. Препарат сорафениб (Нексавар), являющийся мультикиназным ингибитором, влияющим на ангиогенез и пролиферацию опухолевых клеток, приводит к достоверному улучшению безрецидивной выживаемости больных распространенными формами почечно-клеточного рака и обладает хорошей переносимостью, не ухудшая качества жизни пациентов.

About the authors

B Ya Alekseev

МНИОИ им. П.А.Герцена, Москва

P V Shegay

МНИОИ им. П.А.Герцена, Москва

References

  1. Godley P.A, Taylor M. Renal cell carcinoma. Curr Opin Oncol 2001; 13: 199–203.
  2. Jemal A, Tiwari R.C, Murray T et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54 (1): 8–29.
  3. Чиссов В.И., Старинский В.В., Петрова Г.В. (ред.) Злокачественные новообразования в России в 2005 г. М., 2007.
  4. Janzen N.K, Kim H.L, Figlin R.A et al. Surveilance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am.
  5. Motzer R.J, Bacik J, Murphy B.A et al. Interferon - alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289–96.
  6. Motzer R.J, Bacik J, Schwartz L.H et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22 (3): 454–63.
  7. Motzer R.J, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163: 408–17.
  8. Fojo A.T, Shen D.W, Mickley L.A et al. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug - resistance gene. J Clin Oncol 1987; 5: 1922–7.
  9. Vogelzang N.J, Priest E.R, Borden L. Spontaneous regression of hystologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year follow - up. J Urol 1992; 148: 1247–8.
  10. Oliver R.T.D, Mehta A, Barnett M.J. A phase 2 study of surveillance in patients with metastatic renal cell and assessment of response of such patients to therapy on progression. Mol Biother 1998; 1: 14–20.
  11. Mc Dermott D.F, Regan M.M, Clark J.L et al. Randomized phase III trial of high - dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 133–41.
  12. Yang J.C, Sherry R.M, Steinberg S.M et al. Randomized study of high - dose and low - dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21: 3127–32.
  13. Coppin C, Porzsolt F, Awa A et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; CD001425.
  14. Bergers G, Song S, Meyer-Morse N et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 3: 1287–95.
  15. Herrmann E, Brinkmann O.A, Bode M.E et al. Histologic subtype of metastatic renal cell carcinoma predicts response to combined immunochemotherapy with interleukin 2, interferon a and 5-fluorouracil. Eur Urol. In press. doi: 10.1016/j.eururo.2006.11.003.
  16. Maxwell P.H, Wiesener M.S, Chang G.W et al. The tumour suppressor protein VHL targets hypoxia - inducible factors for oxygen - dependent proteolysis. Nature 1999; 399: 271–5.
  17. Kaelin Jr. W.G. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002; 2: 673–82.
  18. Rini B.I, Small E.J. Biology and clinical development of vascular endothelial growth factor - targeted therapy in renal cell carcinoma. J Clin Oncol 2005; 23: 1028–13.
  19. de Paulsen N, Brychzy A, Foumier M.C et al. Role of transforming growth factor - alpha in von Hippel - Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci USA 2001; 98: 1387–92.
  20. Gollob J.A, Wilhelm S, Carter C et al. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006; 33: 392–106.
  21. Schwartz G, Dutcher J.P, Vogelzang N.J et al. Phase 2 clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer. Proc Am Soc Clin Oncol 2002; 21: 24a (abstract no. 91).
  22. Ravaud A, Gardner J, Hawkins R et al. Efficacy of lapatinib in patients with high tumor EGFR expression: results of a phase III trial in advanced renal cell carcinoma (RCC). J Clin Oncol 2006; 24 (Suppl.): 217s (abstract no. 4502).
  23. Motzer R.J, Amato R, Todd M et al. Phase II trial of anti - epidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 2003; 21: 99–101.
  24. Yang J.C, Haworth L, Sherry R.M et al. A randomized trial of bevacizumab, an anti - vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427–34.
  25. Hudes G, Carducci M, Tomczac P et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon - alpha (IFN) or the combination of TEMSR + IFN in the treatment of first - line, poor - risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol 2006; 24 (Suppl.): 2s (abstract no. LBA4).
  26. Ratain M.J, Eisen T, Stadler W.M et al. Phase II placebo - controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505–12.
  27. Hurwitz H, Dowlati A, Savage S et al. Safety, tolerability and pharmacokinetics of oral administration of GW786034 in patients with solid tumors. J Clin Oncol 2005; 23 (Suppl. 16S): 195s (abstract no. 3012).
  28. Motzer R.J, Michaelson M.D, Redman B.G et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet - derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16–24.
  29. Motzer R.J, Rini B.I, Bukowski R.M et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516–24.
  30. Motzer R.J, Hutson T.E, Tomczac P et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon - alfa (IFN-a) as first - line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006; 24 (Suppl.): 2s (abstract no. LBA3).
  31. Amato R.J, Misellati A, Khan M et al. A phase II trial of RAD001 in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006; 24 (Suppl.): 224s (abstract no. 4530).
  32. Wilhelm S, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum anti - tumor activity and targets raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Clin Cancer Res 2004; 64: 7099–109.
  33. Awada A, Hendlisz A, Gil T et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005; 92 (10): 1855–61.
  34. Strumberg D, Richly H, Hilger R.A Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23 (5): 965–72.
  35. Escudier B, Szczylik C, Demkow T et al. Randomized phase II trial of the multi - kinase inhibitor sorafenib versus interferon (IFN) in treatment naive patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006; 24 (Suppl.): 18s (abstract no. 4501).
  36. Escudier B, Eisen T, Stadler W et al. Sorafenib in advanced clear - cell renal carcinoma. N Engl J Med 2007; 356: 125–34.
  37. Elsen T, Bukowski R.M, Staehler M et al. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival. J Clin Oncol 2006; 24 (Suppl): 223s (abstract 4524).
  38. Motzer R.J, Hutson T.E, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal - cell carcinoma. N Engl J Med 2007; 356 (2): 115–24.

Copyright (c) 2007 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies